EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips.

The Morning After

EyePoint moved fast. Within days of the LUCIA readout, the company announced a sweeping restructuring: 53% of the workforce gone, both Phase 3 studies discontinued early, and a pivot to preserve whatever capital remained.

To put that in human terms, EyePoint had about 214 employees as of earlier this year. A 53% cut means roughly 113 people lost their jobs. The company expects to spend about $9 million on severance and separation costs, with most layoffs hitting in Q4 2026 and wrapping up by mid-2027.

The restructuring should save around $30 million per year, money EyePoint says it will redirect toward its remaining program: DURAVYU for diabetic macular edema (DME), a different eye disease with its own set of unmet needs. Whether investors have the patience to stick around for that story is another question entirely.

Why Beating the Standard Was Always a Long Shot

Wet age-related macular degeneration (wet AMD) is a condition where abnormal blood vessels leak fluid into the retina, slowly stealing your central vision. The standard treatment involves regular injections of anti-VEGF drugs directly into the eye. Yes, it sounds awful. Yes, it works remarkably well.

That's actually the problem for anyone trying to compete. Drugs like aflibercept (brand name Eylea), faricimab (Vabysmo), and ranibizumab biosimilars already deliver strong results. The competitive battle in wet AMD has shifted from "does this drug work?" to "can patients get fewer injections while paying less?"

DURAVYU was a sustained-release implant designed to reduce how often patients need treatment. Think of it like a slow-release fertilizer pellet for your lawn, except it sits inside your eye and dispenses medicine over months. The concept is compelling: fewer trips to the doctor, fewer needles in your eyeball. But the clinical bar is high. You still have to match the vision outcomes of standard injections, and EyePoint couldn't clear it.

EyePoint Isn't Alone in the Wreckage

This pattern has become painfully familiar in ophthalmology. Opthea, another biotech chasing wet AMD, saw its Phase 3 candidate sozinibercept fail and responded by cutting 65% of staff, eventually ramping that to over 80%, with even the CEO departing. Late-stage ophthalmology trials are expensive, endpoints are binary (you hit them or you don't), and the market has zero tolerance for ambiguity.

Not every eye-care bet has gone wrong, of course. Merck paid up to $3 billion to acquire EyeBio in 2024, signaling that strategic buyers will still write big checks for differentiated programs. But the keyword is "differentiated." If your drug is trying to match (not beat) an existing therapy and it can't even do that, the market treats it like a dead end.

The broader trend here is capital discipline. In a previous era, a biotech might have tried to spin the LUGANO miss, raise more cash, and push forward. In 2026, the playbook is different: miss a Phase 3 readout and you immediately cut staff, shut trials, and conserve runway. Companies are treating late-stage results as a hard reset, not a speed bump.

What's Left in the Tank?

EyePoint isn't dead yet. The company still has its DME program, and DURAVYU's sustained-release technology could find a better fit in a disease where the competitive dynamics are different. DME has its own unmet needs around treatment burden, and the bar may be more forgiving than it was in wet AMD.

But let's be honest: a stock trading under fifty cents, a workforce cut in half, and two failed pivotal trials is not exactly a position of strength.

For EyePoint's remaining 100-odd employees, the mission is clear: prove that DURAVYU works in DME before the money runs out. For the rest of biotech, the lesson is equally clear. In ophthalmology, matching the standard of care sounds like a modest goal until you realize how brutally high that standard actually is.

The Cancer That Disappeared in Every Single Patient

GSK's dostarlimab just won FDA approval for a specific type of rectal cancer after trial results that stunned the oncology world: a 100% clinical response rate in early cohorts. For eligible patients, it could mean beating cancer without chemo, radiation, or surgery.